ClinicalTrials.gg

Program

stem bromelain

Also written as “EscharEx (EX-03)”, “EX-03” and “EscharEx (5% EX-02 formulation)”.

Its studies are mostly in Varicose Ulcer · Leg Ulcer · Carcinoma, Basal Cell, led by MediWound.

Furthest: phase 3, since Aug 4, 20247 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MediWound73 open or runningphase 3since Aug 4, 2024Dec 19, 2013Dec 2026phase 3 · NCT06568627

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2013First study: phase 2 study in Hard to Heal WoundsFirst studyNCT02020746 · 111 enrolled · Israel
  2. Jun 20, 2018Phase 2 study in Varicose UlcerNCT03588130 · 120 enrolled · United States, Switzerland
  3. Mar 16, 2021Phase 2 study in Varicose UlcerNCT04817228 · 12 enrolled · United States
  4. May 6, 2021Phase 2 study in Superficial Basal Cell CarcinomaNCT05157763 · 32 enrolled · United States
  5. Aug 4, 2024Phase 3 study in Varicose UlcerNCT06568627 · 216 planned · United States, Austria, Canada and more
  6. Oct 29, 2024Phase 2 study in Venus Leg UlcersNCT06690177 · 45 planned · United States, Poland
  7. May 4, 2026Phase 2 study in Varicose UlcerNCT07692178 · 20 planned

Ahead

  1. Dec 2026Primary completion: phase 3 study in Varicose UlcerNCT06568627
  2. Aug 2028Primary completion: phase 2 study in Varicose UlcerNCT07692178
  3. Nov 4, 2028Primary completion: phase 2 study in Venus Leg UlcersNCT06690177

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07692178Varicose Ulcer2Not yet recruitingAug 202820
NCT06690177Venus Leg Ulcers · United States, Poland2Not yet recruitingNov 4, 202845
NCT06568627Varicose Ulcer · United States, Austria, Canada and more3RecruitingDec 2026216
NCT05157763Superficial Basal Cell Carcinoma · United States2UNKNOWNMay 202232
NCT04817228Varicose Ulcer · United States2CompletedMay 6, 202212
NCT03588130Varicose Ulcer · United States, Switzerland2CompletedDec 7, 2021120
NCT02020746Hard to Heal Wounds · Israel2CompletedDec 5, 2017111

How it is read

Names in the registry

  • “EscharEx (EX-03)”, 2 entries
  • “EX-03”, 1 entry
  • “EscharEx (5% EX-02 formulation)”, 1 entry
  • “EscharEx (EX-02 formulation)”, 1 entry
  • “EscharEx 5% (EX-02 formulation)”, 1 entry

Codes read as this program: EX03.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.